Phase Genomics, a Seattle, WA-based genomics technology development company, raised $1.5M in funding.

总部位于华盛顿州西雅图的基因组技术开发公司Phase Genomics筹集了150万美元的资金。

Bill & Melinda Gates Foundation provided the funding.

比尔和梅琳达·盖茨基金会提供了资金。

The company intends to use the funds to develop a new antimicrobial discovery platform.

该公司打算利用这笔资金开发一个新的抗菌药物发现平台。

Led by Ivan Liachko, PhD, Founder and CEO, Phase Genomics applies proprietary proximity ligation technology to enable chromosome-scale genome assembly, microbiome discovery, as well as analysis of genomic variation and genome architecture. In addition to a comprehensive portfolio of laboratory and computational services and products, including kits for plants, animals, microbes, and human samples, they also offer a genome and metagenome assembly and analysis software.

Phase Genomics由创始人兼首席执行官Ivan Liachko博士领导，应用专有的邻近连接技术，实现染色体规模的基因组组装，微生物组发现，以及基因组变异和基因组结构分析。除了全面的实验室和计算服务和产品组合，包括植物、动物、微生物和人类样本的工具包外，他们还提供基因组和宏基因组组装和分析软件。

Commenting on the news, Ivan Liachko said: “Our work at the frontier of microbiome research has unlocked a wealth of new insights on phages, the viruses that infect bacteria. Now, with support from the Gates Foundation, we’re harnessing our global phage database with the goal of improving human and environmental health and providing a critical alternative to traditional antibiotics.“

伊凡·利亚奇科（Ivan Liachko）在评论这条新闻时表示：“我们在微生物组研究前沿的工作为噬菌体（一种感染细菌的病毒）提供了丰富的新见解。现在，在盖茨基金会的支持下，我们正在利用全球噬菌体数据库，旨在改善人类和环境健康，并为传统抗生素提供关键替代品。”